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ABSTRACT
The objective of this study was to maximize the in vitro transcorneal release, the intraocular pressure (IOP)
lowering effect and the duration of action, of the Latanoprost acid (LAT) ophthalmic gels. The in vitro
transcorneal release of LAT from a first set of gel formulations containing different concentrations of Azone
(as enhancer) with a fixed concentration of C-974® (as mucoadhesive) was studied. The formulation that
showed the greatest permeability at the lowest Azone concentration was selected for the preparation of a
second set of ocular gels containing different C-974® concentrations. Their in vitro permeabilities were
evaluated, and the C-974® concentration yielding the greatest in vitro permeability was chosen. The in vivo IOP-
lowering efficacy study for the scaled-up formulations from both sets of the test formulations was performed
using a Tono-pen Avia® tonometer in rabbits for 4 consecutive days. To determine the duration of action, the
most effective formulations were used for a single-dose study, and the IOP was measured at predetermined
intervals until the IOP base-line was reestablished. The majority of the tested formulations showed significant
but varied augmentations in both the in vitro and in vivo permeability results. The formulations GAZ-4 and
GC-4 showed the greatest IOP lowering effects, i.e., 7.8±1.8 mmHg and 6.5±2.1 mm Hg, respectively. It is
particularly noteworthy that for both formulations the IOP lowering effect continued for 24 hours. Their
duration of action in the single-dose study were 47±2.25 hours and 48±1.5 hours, respectively. It was
concluded that the in vitro release, onset, magnitude and duration of action of the LAT gels were increased and
extended for up to 2 days for the two gel formulations.  
KEY WORDS: Azone, corneal transport, ocular delivery, ocular enhancers, Carbopol-974®, glaucoma, IOP lowering
effect, mucoadhesive, thixotropy, intra ocular pressure
INTRODUCTION
Glaucoma is a progressive optic neuropathy
affecting more than 70 million individuals
worldwide and is a major cause for irreversible
blindness (1). In November 2004, the World
Health Organization reported that glaucoma is
responsible for approximately 4.5 million blind
people, approximately 12% of the total burden
of world blindness. It has been reported that
glaucoma is the second leading cause of
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blindness globally (2). One of the most
important risk factors for the progression of
glaucoma is increased Intra Ocular Pressure
(IOP). Elevated IOP can result in retinal
ganglion cell loss and optic nerve atrophy
leading to irreversible blindness. 
Ocular drugs are usually administered as
aqueous eye drops. Latanoprost is a selective
FP prostanoid receptor agonist with good
therapeutic index in the eye. Latanoprost ((+)-
isopropyl (Z)-7-[(1R,2R,3R,5S(3,5-dihydroxy-2-
[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-
heptenoate) is an ester prodrug analogue of
prostaglangin F2α that has been studied for
potential treatment of primary open-angle
glaucoma and ocular hypertension (3, 4). It is
hydrolyzed by esterases in the cornea reducing
both normal and elevated IOP by increasing the
uveoscleral outflow (5, 6). It is the active
ingredient in Xalatan® eye drops.
The main difficulties for ocular drug delivery in
a therapeutically effective concentration from
ophthalmic delivery systems (ODS) are (a) the
very short average residence time of the
administered dose, particularly ophthalmic
solutions (5-25 minutes) (7, 8), (b) the extensive
pre-corneal loss because of the fast tear
drainage and solvent evaporation and alteration
of drug pharmacodynamics, (c) the high
possibility of excessive loss of drug through the
nasolacrimal drainage that may cause systemic
effects and/or side effects (9), (d) the very
limited accommodation capacity of the eye, that
is 10-30 μl for blinking and non-blinking
human eye, respectively and (e) the inherent
physiological involuntary defense mechanism of
the eye (blinking and tearing). Subsequently, the
ocular bio-efficacy of topically applied ocular
drug drops is very low, only 1-10% (10, 11). 
The corneal membrane consists of three
essential layers, i.e., the epithelium, stroma and
the endothelium. The epithelium layer is
lipophilic and contains approximately 100-fold
greater amount of lipid material per unit weight
than the stroma. Therefore, it represents the
main barrier for the hydrophilic (i.e., poorly
lipid soluble) drug molecules. On the other
hand, the stroma which is a hydrophilic, gel-like
structure represents a moderate barrier for
hydrophobic drug molecules. Despite the
lipophilic nature of the endothelium it does not
serve as a barrier for either lipophilic or
lyophobic drug molecules because it has a thin,
single-layer structure with relatively large
paracellular junctions. Therefore it is more
easily crossed through trans-cellular, pore-
cellular and para-cellular transport pathways
(12). The drug molecule should therefore
ideally have biphasic partitioning properties to
be able to successfully cross the corneal
membrane (13-17).
Ocular therapy presents a unique challenge
when it comes to delivery of a drug with
pharmacologically effective levels. Studies have
shown that the outmost layer (i.e., the
epithelium penetration) is commonly the rate-
limiting step to the transcorneal transport of
hydrophilic drug molecules. Thus, drug
molecules must have sufficient lipophilicity to
be able to penetrate this barrier (18). One
approach used to bypass the epithelium barrier
is to incorporate a suitable viscosity improving
agent (VIA) to prolong the contact-time of the
drug with the absorbing surfaces, and a corneal
penetration enhancer to expedite the trans-
corneal transport. Nevertheless, increasing the
viscosity of the aqueous ophthalmic drops to a
viscosity range of 5–25 mPa. provides in most
cases a limited or insufficient increase in the
contact time with the corneal absorbing tissues
(19, 20) and may even lead to a quantifiable
decline in the diffusion of the drug molecule.
Other formulation approaches for maximizing
the therapeutic efficacy of ocular drugs include
using (a) extended release dosage forms with
water-soluble polymers (21, 22) and (b) the
preparation of a lipophilic ion-pair from the
drug molecule and the excipients (23, 24).





Carbopol® polymers are very efficient viscosity
improving (thickeners) and suspending agents,
as well as, stabilizers at low concentrations (0.1-
3.0 wt %). All Carbopol® polymers are high
molecular weight, cross-linked polyacrylic acid
polymers. The main differences between these
polymers are (a) the crosslinker type, (b) density
and (c) solvent used to prepare the polymer (25,
26). Different Carbopol® grades are generally
used as thickeners (viscosity improving agents),
mucoadhesives or bioadhesives for the
preparation of a wide variety of pharmaceutical
dosage forms including solid, semi-solid dosage
forms (ophthalmic and cutaneous gels),
emulsions, suspensions, liquids (with a wide-
range of viscosities and rheological charac-
teristics), nasal, rectal, intestinal, buccal, vaginal,
and in tablets formulation (27, 28). However,
the mucoadhesiveness differ and for example
Carpobol® C-974® has a greater mucoadhesive-
ness compared with C-971® (29). 
A common approach to expedite the absorption
of ocular drugs is the incorporation of an ocular
penetration enhancer(s) (30-32). The limitations
of some enhancers include irritation and
reversible morphological changes in the corneal
membrane (33, 34). An ideal ocular permeability
enhancer must be inert, safe, non-allergenic
non-irritant, shorten the onset of action,
physically and chemically compatible with the
drug molecule and other excipients, and
cosmetically acceptable, potent with the
minimum concentration with both hydrophilic
(in particular) and lipophilic drugs. Azone (1-
dodecylazacycloheptan-2-one) meets the
aforesaid requirements of an ideal enhancer (35,
36). The corneal penetration of hydrophilic
compounds acetazolamide, cimetidine,
guanethidine, and sulfacetamide increased by at
least 20-fold using 0.1% Azone (37). Azone was
reported to be effective in delivering
immunologically active concentrations of
cyclosporine following topical application to the
cornea (35, 38, 39).
To date, the vast majority of research carried out
using Azone has been in in vitro models and/or
in animals without ensuring the relevance of
these studies to humans through in vivo studies.
Further, it is difficult to correlate the data from
these studies because of differences in
methodology, inter/intra-laboratory variability,
animal model and selection of drugs. Therefore,
one of the important indirect objectives for this
study is to draw the attention to the uniqueness
of Azone as a very potent, safe, nonirritant, and
effective permeation enhancer. Azone could
provide an attractive opportunity for
incorporation into formulations used in
preclinical and/or human studies (35, 41, 42).
The objective of this study was to develop and
characterize ocular delivery systems that would
be convenient, provide extended, possibly cont-
rolled drug release and increased therapeutic
effect. Therefore, it was necessary to (a) design,
prepare and quantitatively determine the in vitro
permeability of different LAT gel formulations
containing combinations of various
concentrations of C-974® (as a mucoadhesive)
and Azone (as a corneal penetration enhancer),
and (b) to evaluate in vivo the increase and
magnitude of the IOP lowering effect of LAT




Rabbits and corneas of adult male New Zealand
albino rabbits weighing approximately 3.0-4.0
kilograms each were used throughout this study.
The animals were provided by the King Fahd
Medical Research Center, Jeddah, Saudi Arabia.
The animals used were approved by the
Institutional Review Board for Animal
Research/Studies who ensured the care and use
of animals conformed with the Declaration of
Helsinki and the Guiding Principle in Care and
Use of Animals (DHEW publication NIH 80-
23) and met the “Principles of Laboratory





Animal Care” (NIH publication #85-23, revised
1985).
Drug and Chemicals
Latanoprost free acid (LAT), Azone, sodium
octane sulfonate, acetonitrile and benzalkonium
chloride were purchased from Sigma Aldrich
Chemical Co., St. Louis, MO). Carpobol-974®
(C-974®) was obtained from Lubrizol Advanced
Materials, Inc. 9911 Brecksville Road,
Cleveland, OH. Sodium chloride and
hydrochloric acid were obtained from Spectrum
Chemical Co., Gardena, CA. C-943® and
sorbitol were provided by Fisher Scientific Co.,
Fair Lawn, NJ. Analytical grades of disodium
edetate dihydrate (EDTA) were purchased from
Merck KGaA (Germany). All other chemicals
used in this study were commercially available
compounds of  specia l  reagent  or
analytical/HPLC grade and were used as
received.
Equipment
A PermeGear Flow Type Franz diffusion
system with vertical cells (PermeGear, Inc.,
Hellertown, PA USA), a water auto-sampler
HPLC system with chime station, variable wave
length UV detector, (Water Associates, Inc.,
Milford, MA, USA), and a HPLC column-(RX-
C8, 25-cm x 4.6 mm, 5μm) (ChromTech
International AB, Hägersten, Sweden) were used
for the experiments. A thermostatically
controlled water bath, water bath shaker,
sonicator, hot- plate/stirrer, and pH meter were
obtained from Fisher Scientific Co., Fair Lawn,
NJ. USA. A Touchless Tono-Pen® Avia
tonometer made by Reichert, Inc., NY, and
Millipore filter paper, (0.45μm, HA), were
obtained from Millipore corporation, Bedford,
MA, USA.
HPLC Assay of LAT
A high performance liquid chromatography
(HPLC) method was employed using a
Kromasil RX- C-18 column maintained at room
temperature, with a variable UV detector set at a
wavelength of 210 nm. The mobile phase
consisted of a mixture of acetonitrile and 0.05 M
potassium phosphate buffer (70:30 v/v), pH 3.0
and flow rate of 0.5 ml/min. The mobile phase
was then purified by filtration under vacuum
using a 0.45μm filter and degassed by sonication
for up to 20 minutes. An injection of 1.0
microliter taken from samples of 1 ml was used
for the quantitative analysis of LAT content
(43). Analyses of both negative control (LAT-
free formulation) and positive control (LAT-
containing formulations) showed that none of
the additives used including Azone interfered in
the quantitative specific assay methodology for
LAT contents in all tested formulations.
Preparation of LAT ophthalmic gel formulations
Compositions of the test ophthalmic gel
formulations are shown in Tables 1 and 2.
Table 1 shows the composition of the LAT
ophthalmic gel formulations that were prepared
with various concentrations of Azone as a
transcorneal release enhancer with a fixed
concentration (1.5%) of C-974® as a
mucoadhesive aiming to identify the lowest
concentration of Azone that induced the
greatest permeability. 
Table 1 Composition of the second set of LAT test
ophthalmic gel formulations containing different
concentrations of Azone as penetration enhancer and
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*Isotonic test gel formulations were first prepared and the isotonicity was
maintained using sorbitol when necessary.





Table 2, shows the composition of the LAT
ophthalmic gel formulations that were prepared
with a fixed (lowest) concentration of Azone
(0.5%) that induced the greatest permeability,
with varying concentrations of C-974® to
identify and scale-up the best formulation(s)
amongst the two test sets of LAT ophthalmic
gel formulation for use in further in vivo IOP
lowering efficacy studies. The tonicities of the
gel formulations were adjusted with sorbitol and
the final pH values of all formulations were
adjusted to 6.9, i.e., the pH value of the
commercially available Latanoprost Xalatan®
eyedrops with 0.1N HCL (44).
Table 2 Composition of the first set of LAT test
ophthalmic gel formulations containing different
concentrations of C-974® as Mucoadhesive with fixed
concentration (0.5%) of Azone as enhancer.












































*Isotonic test gel formulations were first prepared and the isotonicity was
maintained using sorbitol when necessary.
**Isotonic negative control solution (0.0% C-943®) was first prepared and the
isotonicity was maintained using 0.9% saline. 
***This set of formulations were prepared using the formulation of LAT that
gave the best in vitro permeability parameters using Azone 0.375%.
The ingredients of each formulation were
prepared, mixed and sterilized by filtration as
aqueous solutions using 0.22μm Millipore filters.
C-974® in its dry powder form was subjected to
autoclaving at 121°C for 30 minutes and was
incorporated into the formulation under aseptic
conditions. Isobel and Stanley have reported
that there was little or no change in the viscosity
or pH upon repeatedly subjecting a Carbopol®
polymer gel to autoclaving at 121°C for 30
minutes (45).
In vitro corneal permeability studies
The animals were sacrificed by administering an
overdose of a sodium pentobarbitone solution
via the marginal ear vein. Then the corneas were
excised and mounted in a penetration chamber.
Each fresh cornea was then rinsed with normal
saline water and gently mounted with the
epithelial surface facing the donor half-cell
medium using a small pinch clip over a receiver
half-cell containing the receiver fluid and stirred
gently with magnetic stirrers (about 600 RPM).
The permeation assembly was carried out using
a modified, fully equipped Franz vertical
transcor-neal diffusion system employing a
finite dose technique. Samples from the receiver
compartment were drawn carefully at
predetermined time intervals and replaced
immediately with equal volumes of fresh pre-
heated degassed medium (15, 46, 47). Then the
LAT permeability parameters for each test
formulation were calculated. All the experiments
were replicated 3 times at 34EC. The
concentration in the donor half-cell was
determined at the end of each experiment. All
samples were analyzed for LAT using HPLC.
The apparent permeability coefficients (Papp) of
the test compounds were calculated using
Equation 1:
Eq 1P
x 60 x  600
app
Q
t AC  





Where, ΔQ/Δt is the steady-state flux across the
cornea (mg.cm -2.hr-1), A is the available corneal
surface area (cm2) for diffusion and C0 is the
initial drug concentration (mg.ml-1) in the donor
compartment at t = 0. Flux per unit surface area
1/A x ΔQ/Δt was calculated from the slope of
the linear portion of the cumulative amount
permeated per unit surface area versus time. The
significance of any statistical differences
between the compounds in the amount
permeated at each time point and the mean
values were calculated using a one-way analysis
of variance (ANOVA) using SPSS 16.0.1





software, (SPSS Inc., Chicago, IL, USA) and the
criterion for statistical significance was p< 0.05. 
In vivo IOP measurement
In vivo IOP lowering effects of LAT-gel
formulations
The in vivo studies were performed on
normotensive un-anaesthetized albino rabbits
weighing 3.0-4.0 kilograms. The rabbits were
individually caged at a controlled temperature
and kept on 12/12-hour light/dark to mimic a
normal life-cycle, fed a regular diet with free
access to water. The required number of the
experimental animals were randomly divided
into groups of 10-rabbits per formulation.
The formulations that showed the highest
permeability parameters (Tables 3 and 4), that is,
GAZ-3, GAZ-4 (identical to GC3), and GAZ-4
from the first set together with the formulations
GC-1, GC-2, GC-4 and the recognized
reference standard were used for the in vivo IOP
lowering efficacy studies. Each formulation was
moderately shaken with an electric/vortex
shaker for about 20-30 seconds to ensure
dosage uniformity, accuracy and to facilitate the
withdrawal and dosing procedure. Thereafter, a
dose of 50 μl from each test formulation was
administered once a day for 4 successive days
onto the conjunctival sac using a positive
displacing pipette to each individual rabbit in
each animal group. A Tono-Pen® Avia
tonometer was used for measuring the IOP
baseline, as well as, the in vivo IOP lowering
effects after predetermined time intervals i.e.,
after the first 3 hours (the reported average
onset of action) and then after each additional
24 hours. Acute eye irritation/ corrosion and
ocular irritation potential of the gel formulations
were tested. The irritation test was carried out in
accordance with the Organization for Economic
C o o p e r a t i o n  a n d  D e v e l o p m e n t
(OECD/OCED) test No. 405 guideline 405
(48). 
Extended in vivo IOP lowering effects of
promising LAT-gel formulations
The IOP for each animal was recorded at the
end of each day throughout the experiments.
Formulations that exhibited promising IOP
lowering effects were subjected to further
studies to determine the duration of the action
i.e., from the time of dosing until re-establishing
the IOP base-line. For this experiment, the
experimental animals were randomly divided
into equal groups (10-rabbits/group). The
animals were handled and housed as stated
previously. The animals were then treated as
described previously with a single-dose of each
formulation. The IOP lowering effects were
measured at appropriate time intervals until the
IOP baseline was re-established.
RESULTS AND DISCUSSION
In vitro corneal permeability of the LAT-gel
formulations
The first set of LAT gel formulations containing
different concentrations of Azone as
transcorneal penetration enhancer and a fixed
concentration (1.5%) of C-974® as a
mucoadhesive and viscosity improving agent
(crosslinkage thickener) were prepared.
Formulation GAZ-0Control did not contain Azone
and served as a negative control (Table 1).
Figure 1 shows the cumulative amounts of LAT
(μ g/ml) represented as mean ± SD % of total
LAT released from the test formulations into
the receiver compartment of the diffusion cell as
a function of time in hours (n=3). Table 3
shows the calculated permeability parameters
for the first set of LAT formulations including,
mean steady-state flux (Jss), μg.cm
-2.sec -1 , IOP
Papp , and the enhancement factor (EF)
calculated as Papp-Tests/Papp-control. The data in Table
3 also showed that the transport characteristics
of LAT through excised fresh corneal





Figure 2 Relationship between the concentration of Azone as a transcorneal
permeation enhancer and the in vitro apparent permeability coefficient of LAT
ophthalmic gel formulations across freshly excised rabbit’s cornea (n=3±SD).
Figure 1 Mean total % of LAT delivered into the receiver chamber of an automated
Franz’s diffusion system from LAT eye gels containing different concentrations of Azone
corneal penetration enhancer and fixed concentration (1.5%) of C-974® as a mucoadhesive
across freshly excised rabbit’s cornea (n=3±SD).
membrane significantly (p<0.01) increased with
increasing concentration of Azone up to a
concentration of 0.5%.
However, a higher concentration (i.e., 0.625%)
did not show any significant increase in the
permeability parameters. Figure 2 indicates a
linear (R=0.9418) and direct relationship
between the apparent permeability coefficient
(Papp, cm.sec
-1) for this set of LAT ophthalmic
gel formulations and the percentage of the
added Azone as a permeation enhancer. In
other words, the temporal pattern of LAT
release from the test formulations appears to be





Figure 3 Mean total % of LAT delivered into the receiver chamber of an automated
Franz diffusion system from LAT eye gels containing different concentrations of C-974®
as a mucoadhesive and fixed concentration (0.5%) of Azone as a corneal penetration
enhancer across freshly excised rabbit’s cornea (n=3±SD).
a single-valued function of the concentration of
Azone, i.e., concentration dependent. This could
be related to, but not limited by, the assumption
that the enhancement of drug permeation by
Azone is due to its ability to reversibly increase
the fluidity of the intercellular lipid bilayers of
the corneal membrane. Thereby it lessens the
diffusional resistance of the corneal epithelial
layer to drug, i.e., increasing drug diffusiion and
partitioning. 
A different but related hypotehsis is that Azone
evokes its effect as permeation enhancer by
increasing the drug solubility and/or changing
the ratio between ionized and unionized drug
molecules in favor of the later (16, 36, 49). The
enhancement factor (EF) was also found to be a
function in the concentration of Azone.
Accordingly, formulations GAZ-3, GAZ-4,
GAZ-5 together with the reference standard
Xalatan® 0.005% eye drops were selected for
additional in vivo IOP lowering experiments.
When developing a medicinal drug product it is
highly recommended that the lowest possible
number of excipients is included at their lowest
effective concentration. Therefore, a second
set of LAT gel formulations containing a fixed
concentration (0.5%) of Azone (lowest concen-
Table 3 Effects of different concentrations of Azone
upon the permeability parameters of LAT Formulations
containing fixed concentration 1.5% C-974® as
































tration that induced the highest permeability
parameters in the first set of LAT ophthalmic





Figure 4 Relationship between the concentration of Carbopol® as a mucoadhesive and
the in vitro apparent permeability coefficient of LAT ophthalmic gel formulations across
freshly excised rabbit’s cornea (n=3±SD).
gel formulation) as transcorneal penetration
enhancer along with different concentrations of
C-974® as a mucoadhesive and viscosity
improving agent (crosslinker/thickener) were
prepared. Formulation GC-0 Control did not
contain C-974® (simple eye drops) and served as
a negative control (Table 2). Figure 3 shows the
cumulative amounts of LAT (μg/ml)
represented as mean ± SD % of total LAT
released from the test formulations into the
receiver compartment of the diffusion cell as a
function of time in hours. Table 4 shows the
calculated permeability parameters for the
second set of LAT formulations including,
mean steady-state flux (Jss), μg.cm
-2.sec-1, IOP
Papp, and the enhancement factor (EF) calculated
as Papp-Tests/Papp-control. The data in Table 4 also
show that the transport characteristics of LAT
through excised fresh corneal membrane
decreased significantly (p<0.01) with increased
concentrations of C-974®. 
Figure 4 shows that the apparent permeability
coefficient remains constant up to a Carbopol
concentration of 1.5% and then decreases
significantly. The exact correlation between
viscosity of the vehicle and transcorneal
penetration is difficult to be established as it is
generally not the rate-limiting step in the corneal
absorption process. This is complicated by the
fact that the release of a penetrant from the
vehicle of formulation is governed by numerous
factors related to the physicochemical properties
of the drug, vehicle, extent of their mutual
intermolecular attractive forces (if exists) and to
Table 4 Effects of different concentrations of C-974® on
the permeability parameters of LAT formulations
containing fixed concentration 0.5% Azone as penetration
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Figure 5 Mean IOP lowering effects expressed as the difference from the base line
(23+3.0 mmHg) for scaled up LAT ophthalmic gels containing different
concentrations of Azone as a corneal penetration enhancer compared to the reference
standard (Xalatan®) in normotensive New Zealand Rabbits (n=3±SD).
the portioning of the drug from that vehicle to
the absorbing surface (50). However, the
viscosity of the formulation does affect the drug
diffusion. Formulations GC-3 (identical to
formulation GAZ-4) and GC-4 showed
significantly (p>0.01) higher permeability
parameters than formulation GC-5. The in vitro
corneal permeability parameters of formulations
GC-0Control, GC-1 and GC-2 released LAT at a
faster rate than the test formulations of the
second set, particularly during the first ~6, 8 and
10 hours, (depending on the C-974®
concentration). Formulation GC-0Control showed
the fastest onset and the shortest duration of
action at ~18-20 hours, which is shorter than,
but comparable to, that observed with the
reference standard Xalatan® up to ~21-22
hours. Moreover, the formulations GC-1, GC-2,
GC-3 and GC-4 showed thixotropic
p h e n o m e n a ,  i . e . ,  n o n - N e w t o n i a n
fluids/semisolid feature in which viscosity
decreases with the shearing time, and the
subsequently recovers after cessation of
shearing (51, 52) (unpublished data). These
formulations were scaled up for further in vivo
IOP lowering studies. 
 
In vivo IOP measurements
In vivo IOP lowering effects of LAT ophthalmic
gels
The average IOP base line of the normotensive
rabbit (23±2 mmHg) was measured and
recorded prior to the administration of each
dose. Figure 5 shows the ΔIOP for the scaled
up ophthalmic gel formulations of the first set,
i.e., GAZ-3, GAZ-4 and GAZ-5 together with
ΔIOP for LAT commercial ophthalmic solution
(Xalatan®) applied topically once a day for four
successive days. The maximum ΔIOP
measurements for the tested formulations
GAZ-3, GAZ-4, GAZ-5 and Xalatan® were
(7.8±1.8), (6.2±2.0), (5.5±1.7), and (5.6±2.0)
mmHg, respectively. The mean ΔIOP ±SD
values and the onset of action were achieved
within the time range of 1.5-3.5 hours, in direct
correlation with the concentrations of corneal
penetration enhancer (Azone), as well as, the
permeability parameters. Formulation GAZ-3





Figure 6 Mean IOP lowering effects expressed as the difference from the base line
(23+2.0 mmHg) for rationally scaled-up LAT ophthalmic gels containing different
concentrations of C-974® as a mucoadhesive compared to the reference standard
(Xalatan®) in normotensive New Zealand Rabbits (n=3±SD).
containing 0.5% of Azone showed comparable
onset of action but significantly higher ΔIOP
than those with formulation GAZ-5 containing
0.625.0% and with the commercial reference
standard Xalatan®. The assumption that a more
compact gel network assembly and/or complex
could be formed with higher concentrations of
the mucoadhesive, crosslinker C-974® could be
a reasonable explanation for these results. This
might explain the extended duration of action
and possibly reduced LAT release from and
diffusion though such compacted gel (53). The
likelihood of ocular irritation due to the
administration of the test gel formulation or one
of its ingredients was assessed in New Zealand
albino rabbits according to OECD, 2002
protocol (48). Upon inspection, no signs of
ophthalmic irritation (i.e., tearing, redness,
inflammation, and/or swelling) were recorded
with the test gel formulation or any of its
ingredients at the used concentrations during
the course of the experiments.
Figure 6 shows the in vivo ΔIOP measurements
for the scaled up ophthalmic gel formulations
designated GC-1, GC-2, (GC-3/GAZ-4), GC-4
of the second set, and the reference standard
(RS) Xalatan®. The maximum ΔIOP measure-
ments for the formulations of this set were
6.0±2.2, 7.8±1.8, 6.5±2.1, 4.8±1.7 and 6.5±1.5
mmHg, respectively. The onset of action range
for these formulations was 1 to 4 hours. Such a
wide range of the onset of action is likely
because this set of formulations encompasses
formulations that contain different concentra-
tions of the C-974® mucoadhesive (0-2.5%).
The duration of action was a function of the
mucoadhesive concentration. Concentrations of
C-974® greater than 1.5% significantly (p>0.05)
extended the duration of action, but reduced the
efficacy due to delaying the onset of action. The
presence of C-974® as mucoadhesive functions
to increase the contact period with the ocular
absorbing surfaces, i.e., providing more time for
the drug to be delivered, while the addition of
Azone to the formulation increases the
permeability with a resultant increase in the





Figure 7 Mean extended duration of action of the two scale-up LAT ophthalmic gel
formulations (i.e., GC-3/GAZ-4 and GC-4) in normotensive New Zealand Rabbits
(n=3±SD).
ΔIOP. Evidently, the in vitro release and the in
vivo pharmacodynamics for both sets of LAT
ophthalmic gel formulations is largely
dependent on the combined effect of these two
formulation ingredients. 
Extended in vivo IOP lowering effects of
selected LAT-gel formulations
The IOP for each animal was recorded at the
end of each day throughout the previously
described in vivo experiments. Formulations
GAZ-4/GC-3 and GC-4 showed significant
IOP lowering effects, a particularly noteworthy
point being that both formulations sustained the
IOP lowering effect past 24 hours. Figure 7
shows that formulations designated GAZ-
4/GC-3 and GC-4, induced significantly higher
therapeutic IOP lowering effects than that of
the reference standard Xalatan®, i.e., 7.8±1.8
mmHg and 6.5±2.1 mmHg respectively. In
Figure 7 the in vivo ΔIOP lowering effects that
were recorded after the first 3 and 24 hours,
then each two-hours until the 40th hour, and
finally each subsequent hour until the IOP
reestablished the base line (23±2 mmHg) to
exactly determine the duration of actions of the
two formulations. The average IOP lowering
effects for formulations GC-3/GAZ-4 and GC-
4 lasted for 47±2.25 hours, and 48±1.5 hours,
respectively. The IOP lowering effects for the
two ophthalmic gel formulations remained
essentially unchanged during the duration of the
action. This relatively high steady magnitude of
the IOP lowering effect could be partially
explained by the relatively rigid nature of the
channels of C-974® gel micro-matrix
characterized by a very high macro-viscosity and
regions of molecular-dimensions micro-
viscosities. The presence of these channels
could help increase the initial release rate, as well
as, the in vivo IOP lowering effects of LAT-C-
974® containing gels (29, 52, 53).
In vitro release experiments are usually designed
to maintain the drug formulation in constant,
direct contact with the corneal epithelium layer
throughout the entire experiment. However, this
is not true for in vivo experiments or the 





management of patients with glaucoma, where
the ocular therapeutic efficacy of an applied
dose is affected (negatively or positively) by the
unique physiological and anatomical constraints
of the eye in addition to the physicochemical
properties of the drug formulation. The results
of this study suggest that, for an ocular drug
delivery system, the correlation between in vitro
release data and the in vivo efficacy is complex
and controlled by a number of inter-related and
in some cases contradictory factors that should
be taken into consideration prior to developing
ocular drug delivery systems, as well as,
extrapolating or generalizing the in vitro studies
outcomes to the in vivo clinical situation.
In conclusion, the in vitro corneal drug transport,
onset of action, augmenting IOP lowering effect
and increasing the extent of LAT therapeutic
efficacy for the test formulations largely depend
upon the net outcomes of the interaction
between (a) the prolonged residence time of
LAT in conjunctival cavity caused by the
mucoadhesive and crosslinker C-974®, (b) the
accelerated drug transport by the penetration
enhancer (Azone), (c) the reduced diffusivity of
the drug throughout the vehicles of gel
formulations resulting from the increased
viscosity by the thickener, (d) the rheological
and physicochemical characteristics of the
formulation and drug, in addition to (e) the
inherent unique physiological and anatomical
constraints of the eye represent further vital
element that constrains successful development
of ocular delivery systems. As this study shows,
improving the delivery of drugs to ocular tissues
is a non-trivial exercise that involves measuring,
understanding and universalizing the
mechanisms of pharmacodynamics and drug
targeting. Although significant challenges remain
regarding the deconvolution of a plethora of
effects in the delivery of drugs to the eye, the
problem is not unsurmountable. 
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